“…Silverberg and Hurt questioned this prognosis because four of five patients in their series were disease-free for at least 3 years [5]. More recently, findings by Gilks et al [6] for the largest case study were in agreement with those of McKelvey and Goodlin [4] and Kaku and Enjoji [13]. However, Hirai et al reported that most neoplasms in these unfavorable reports were discovered at an advanced stage [7].…”
Section: Discussionmentioning
confidence: 83%
“…An early report suggested an unfavorable prognosis in patients with AM [4]. Silverberg and Hurt questioned this prognosis because four of five patients in their series were disease-free for at least 3 years [5].…”
Section: Discussionmentioning
confidence: 99%
“…In 1963, McKelvey and Goodlin reported five AM cases [4]. In 1975, the term minimal deviation adenocarcinoma was proposed by Silverberg and Hurt [5] for tumors with good differentiation and a good prognosis.…”
The aim of this study was to evaluate the clinical and pathologic features of a rare tumor (adenoma malignum, AM). We retrospectively analyzed the medical records of 18 patients diagnosed with AM at a single institute between March 1992 and November 2009. The median age of the patients was 45.8 years (range 29-76 years) and the mean follow-up period was 49.2 months (range 4-168 months). A preoperative cytologic diagnosis (Papanicolaou smear) of AM was made in 22.2% (4/18) of the cases. Ten (55.6%) of the 18 patients were misdiagnosed with other benign diseases and underwent hysterectomies, which confirmed AM. Sixteen patients with AM were in the early stage (IB1, 11/18; IB2, 5/18) and the other two patients were in the advanced stage. Fourteen of 18 patients (77.8%) had pure AM alone. Adjuvant therapy was administered to eight of the patients (44.4%) with AM. The recurrence rate was zero, but the disease progressed in two of the patients (11.1%), who died of the disease. The 5-year survival rate was 88.8%. A cytological diagnosis of AM based on a Papanicolaou smear is rarely made; a deep biopsy (cone biopsy or endocervical curettage) is necessary to diagnose this rare tumor preoperatively when there is any clinical suspicion of AM.
“…Silverberg and Hurt questioned this prognosis because four of five patients in their series were disease-free for at least 3 years [5]. More recently, findings by Gilks et al [6] for the largest case study were in agreement with those of McKelvey and Goodlin [4] and Kaku and Enjoji [13]. However, Hirai et al reported that most neoplasms in these unfavorable reports were discovered at an advanced stage [7].…”
Section: Discussionmentioning
confidence: 83%
“…An early report suggested an unfavorable prognosis in patients with AM [4]. Silverberg and Hurt questioned this prognosis because four of five patients in their series were disease-free for at least 3 years [5].…”
Section: Discussionmentioning
confidence: 99%
“…In 1963, McKelvey and Goodlin reported five AM cases [4]. In 1975, the term minimal deviation adenocarcinoma was proposed by Silverberg and Hurt [5] for tumors with good differentiation and a good prognosis.…”
The aim of this study was to evaluate the clinical and pathologic features of a rare tumor (adenoma malignum, AM). We retrospectively analyzed the medical records of 18 patients diagnosed with AM at a single institute between March 1992 and November 2009. The median age of the patients was 45.8 years (range 29-76 years) and the mean follow-up period was 49.2 months (range 4-168 months). A preoperative cytologic diagnosis (Papanicolaou smear) of AM was made in 22.2% (4/18) of the cases. Ten (55.6%) of the 18 patients were misdiagnosed with other benign diseases and underwent hysterectomies, which confirmed AM. Sixteen patients with AM were in the early stage (IB1, 11/18; IB2, 5/18) and the other two patients were in the advanced stage. Fourteen of 18 patients (77.8%) had pure AM alone. Adjuvant therapy was administered to eight of the patients (44.4%) with AM. The recurrence rate was zero, but the disease progressed in two of the patients (11.1%), who died of the disease. The 5-year survival rate was 88.8%. A cytological diagnosis of AM based on a Papanicolaou smear is rarely made; a deep biopsy (cone biopsy or endocervical curettage) is necessary to diagnose this rare tumor preoperatively when there is any clinical suspicion of AM.
“…The most common initial symptom is watery vaginal discharge. Several studies have reported a poor prognosis7–9, whereas some found a relatively favorable prognosis similar to that of other well‐differentiated cervical adenocarcinomas5, 10.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.